Comparing vitamin D3 and acyclovir shots for skin warts
Part of Infections, Skin clinical trials.
This trial tests two injected treatments (vitamin D3 or acyclovir) for common skin warts. The goal is to see which one works better for warts that are new or have not gone away with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 12 years or older
- Has one or more skin warts (common, on the bottom of foot, flat, or around nails)
- Not pregnant or breastfeeding
- No weak immune system
- Not allergic to vitamin D3 or acyclovir
- Has not used any wart cream, freezing, or other wart treatment in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection-based treatment for common warts (the bumpy growths on skin caused by a virus). Researchers want to see if this approach works better than current options and is safe for patients.
This study tests two treatments for common warts: a sclerotherapy injection and a candida antigen injection. The goal is to see which one works better to remove warts.
This trial tests two versions of an at-home medicine to see how well they clear warts. Participants are randomly assigned to the study medicine or a placebo (inactive treatment) so researchers can compare results fairly.
This trial tests a medication called cantharidin for treating common warts. It is for people age 2 and older who are generally healthy and have at least one common wart on the body (but not on palms, soles, face, or genitals). Participants cannot use other wart treatments during the study.
This study tests whether cantharidin—a liquid applied directly to common warts—can safely and effectively remove them. Common warts are bumpy growths caused by a virus that appear on hands, feet, and other body areas.
This study is testing an ointment called tirbanibulin to treat warts on the hands of children and teens. It may offer a new option if other treatments haven't worked.
Hear when a new Common Warts (Verruca Vulgaris) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.